← back to database
Mission BioCapital makes pivotal early-stage investments in life-sciences companies, emphasizing therapeutics while also backing diagnostics, medical devices, laboratory tools, and drug delivery. It supports company formation and development with capital, lab infrastructure, and hands-on scientific and operating support. Its Platinum Program provides up to $500,000 of pre-seed capital; its core fund invests at seed and Series A.
Stage focus
Lead / follow
Check size
Ownership target
Specialization
Generalist / Specialist
Specialist
Latest fund size
$143.75M raised to date for Fund VI (SEC Form D, Nov. 2025); prior Fund V was $275M
Latest fund vintage
2024 (Fund VI first sale); 2021 (Fund V)
Investing team
Cassidy BlundellPartner
Chaya PatelPrincipal
Clay RowlandInvestment Associate
Douglas CrawfordManaging General Partner
Jennifer GriffinPartner
Johannes FruehaufGeneral Partner
Josephine BrystingInvestment Analyst
Peter ParkerManaging General Partner
Robert BlazejPartner
Steve TregayManaging General Partner
Ulrik B. NielsenGeneral Partner
Zach CollinsPartner
How to reach them
Notable investments
Sources
missionbiocapital.com ↗missionbiocapital.com/team ↗prnewswire.com/news-releases/mission-biocapital-announces-opening-of-4-million-2026-platinum-program-contest-and-2025-platinum-ticket-investments-302731624.html ↗businesswire.com/news/home/20211104005254/en/Mission-BioCapital-Announces-%24275-Million-Fund-V ↗sec.gov/Archives/edgar/data/2039280/000203928025000007/xslFormDX01/primary_doc.xml ↗venturecapitalarchive.com/venture-funds/mission-biocapital-missionbiocapital-com ↗